Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus DRAXIMAGE MDP 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus DRAXIMAGE MDP 10.
DRAXIMAGE DTPA vs DRAXIMAGE MDP-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in areas of bone turnover, binding via chemisorption to hydroxyapatite crystals, allowing scintigraphic imaging of skeletal lesions.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
555-1110 MBq (15-30 mCi) intravenously for skeletal imaging; administered 2-3 hours before imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Terminal elimination half-life: 2.5 hours (range 2-3 hours); clinically, allows rapid imaging post-injection.
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Renal: 95% within 6 hours; biliary/fecal: <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical